Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $287.43 (market cap $13.46B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.97. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| CRL | PDBC | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | — |
52-Week High | $284.37 | $18.91 |
52-Week Low | $145.57 | $12.90 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.97, up 0.79% today, with a strong bullish technical signal from moving averages. Recent news highlights institutional accumulation, with Geneos Wealth Management increasing its position by 150.6% in Q1 2026 (SEC filing, July 19, 2026), and commodities gaining attention as an inflation hedge amid Middle East tensions.
The ETF offers diversified commodity exposure without K-1 tax forms, but faces risks from commodity price volatility and geopolitical events. While technical momentum is positive, a Seeking Alpha report from June 11, 2026, downgraded PDBC to hold due to weakening commodity momentum, indicating cautious near-term outlook despite long-term inflation-hedging appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
